Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
Bhardwaj N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, Martin R, Chang S, Miller MD, Feld JJ, Sulkowski M, Mangia A, Wertheim JO, Osinusi A, McNally J, Brainard D, Mo H, Svarovskaia ES. Bhardwaj N, et al. Among authors: feld jj. J Viral Hepat. 2018 Apr;25(4):344-353. doi: 10.1111/jvh.12825. Epub 2017 Dec 28. J Viral Hepat. 2018. PMID: 29112331 Clinical Trial.
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Sulkowski MS, Feld JJ, Lawitz E, Felizarta F, Corregidor AM, Khalid O, Ghalib R, Smith WB, Van Eygen V, Luo D, Vijgen L, Gamil M, Kakuda TN, Ouwerkerk-Mahadevan S, Van Remoortere P, Beumont M. Sulkowski MS, et al. Among authors: feld jj. J Viral Hepat. 2018 Jun;25(6):631-639. doi: 10.1111/jvh.12853. Epub 2018 Feb 6. J Viral Hepat. 2018. PMID: 29274193 Clinical Trial.
The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. van der Meer AJ, et al. Among authors: feld jj. J Viral Hepat. 2014 Aug;21(8):568-77. doi: 10.1111/jvh.12185. Epub 2013 Oct 10. J Viral Hepat. 2014. PMID: 24118177
New therapeutic agents for chronic hepatitis B.
Brahmania M, Feld J, Arif A, Janssen HL. Brahmania M, et al. Lancet Infect Dis. 2016 Feb;16(2):e10-21. doi: 10.1016/S1473-3099(15)00436-3. Epub 2016 Jan 13. Lancet Infect Dis. 2016. PMID: 26795693 Review.
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld JJ, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson IM, Dumas EO, King M, Sulkowski M. Alqahtani S, et al. Among authors: feld jj. J Viral Hepat. 2017 Apr;24(4):280-286. doi: 10.1111/jvh.12641. Epub 2016 Dec 9. J Viral Hepat. 2017. PMID: 27935166
370 results